the goal of this study is to compare the efficacy of ustekinumab with infliximab for the treatment of ulcerative colitis aim of the study :
1. Compare effectiveness of ustekinumab versus infliximab therapy in remission achievement in UC patients. 2. Compare safety of ustekinumab therapy versus infliximab therapy in UC 3. To asses quality of life of ustekinumab therapy versus infliximab therapy in UC patients.
Subjects who are voluntarily able to give informed consent
Subjects who can participate in all aspects of this clinical study
Males and females aged from ≥ 18 to ≤ 80 years, at screening visit
Diagnosis of moderate to severe UC established by clinical and endoscopic evidence.
- Previous exposure to IFX or UST or any other in IFX or UST-containing product
Has a history of hypersensitivity or allergies to the ingredients of IFX or UST formulations
Unstable angina
Moderate or severe heart failure (defined as New York Heart Association Class III or IV)